Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2009

View Archived Issues

Provid and U.S. Department of Health & Human Services jointly divulge new Chk2 and RSK2 inhibitors

MRX-1024, an oral D-met suspension, protects against cisplatin-induced ototoxicity in humans

TRPV1-mediated analgesic activity is enhanced by repeated administration of ABT-102

Third quarter highlights at Takeda

CHMP issues positive opinion for Removab for malignant ascites

Nymox updates the FDA in regard to their phase III program for NX-1207

Arana discontinues PMX-53 development for ocular indications

Abbott and Enanta initiate phase I ABT-450 HCV protease inhibitor trial

Anacor presents results from phase II psoriasis trial with AN-2728

AVEO initiates phase Ib/IIa AV-951 trial in advanced breast cancer

AVI BioPharma treats first patient in AVI-4658 Duchenne muscular dystrophy trial

New gamma-secretase inhibitors reported in recent Schering-Plough patent

Seattle Genetics initiates pivotal SGN-35 trial for Hodgkin's lymphoma

Novel MMP-12 inhibitors imparted by AstraZeneca researchers

Obio presents update on company activities

Biosergen discloses novel antifungal agents

ECI concludes CTA with NIA for initiation of phase I clinical trial of ECI-301

sanofi-aventis imparts new cannabinoid CB2 receptor antagonists for pain relief

FDA accepts Nuvo's resubmission of MAA for Pennsaid in osteoarthritis

Conbriza receives positive CHMP opinion for osteoporosis

Eisai and Bial partner for European commercialization of Zebinix

CHMP recommends granting marketing authorization to Nycomed's Pantozol Control

Green tea extracts may neutralize the antitumor effects of bortezomib

Sucampo and Abbott sign Japanese license and commercialization agreement for Amitiza

Target of vitamin D in breast cancer cells identified

NSC-84093 inhibits melanophore migration in vitro

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...